Det medisinske fakultet

Institutt for nevrologi

Produksjonsdato : 2001-01-20
Katalogtype: Kortformat.

1
Aarli, Johan A
Amyotrofisk lateralsklerose - lys i enden av tunnelen? Tidsskr Nor Lægeforen.
119: 2976 1999.

2
Aarli, Johan A
Beta-interferon ved multippel sklerose: Hvem skal behandles? Tidsskr Nor
Lægeforen. 119: 3114 1999.

3
Aarli, Johan A
Late-onset myasthenia gravis. A changing scene. Arch Neurol. 56: 25 - 27
1999.

4
Aarli, Johan A; Engelsen, Bernt A
Occipital lobe epilepsies. Handbook of Clinical Neurology. The Epilepsies.
Elsevier Science B.V. 73: 44, 231 - 243 Amsterdam 1999.

5
Aarsland, Dag; Larsen, JP; Karlsen, K; Lim, NG; Tandberg, E
Mental symptoms in Parkinson's disease are important contributions to
caregiver distress. Int J Ger Psych. 14: 866 - 874 1999.

6
Aarsland, Dag; Larsen, JP; Lim, NG; Tandberg, E
Olanzapin for psychosis in patients with Parkinson's disease with and
without dementia. J Neuropsych Clin Neurosci. 11: 392 - 394 1999.

7
Aarsland, Dag; Larsen, JP; Cummings, JL
Prevalence and clinical correlates of perceptual distortions and
psychosis in Parkinson's disease. A community-based study. Arch Neurol. 56:
595 - 601 1999.

8
Aarsland, Dag; Larsen, JP
Psychosis in basal ganglia disorders:Epidemiology. Mental dysfunction in
Parkinson's disease II. Academic Pharmaceutical Productions 218 - 236
Utrecht, Nederland 1999.

9
Aarsland, Dag; Larsen, JP; Lim, NG; Janvin, C; Karlsen, K; Tandberg, E;
Cummings, JL
Range of neuropsychiatric disturbances in patients with Parkinson's
disease. J Neurol Neurosurg Psych. 67: 492 - 496 1999.

10
Aurlien, Harald; Gjerde, Ivar Otto; Hovstad, Ole Gaute; Karlsen, Bjørn;
Skeidsvoll, Håvard
A new way of building a database of EEG findings. Clin Neurophysiol. 110:
986 - 995 1999.

11
Bindoff, Laurence A
Treatment of mitochondrial disorders: practical and theoretical
issues. Eur J Paediatri Neurol. 3: 201 - 208 1999.

12
Chinnery, PF; Zwijnenburg, PJG; Walker, M; Howell, N; Taylor, RW;
Lightowlers, RN; Bindoff, Laurence A; Turnbull, DM
Non-radom tissue distribution of mutant mtDNA in humans. Am J Med Genet. 85:
498 - 501 1999.

13
Chrzanowska-Lightowlers, Z; Temperley, RJ; McGregor, A; Bindoff, Laurence A;
Lightowlers, RN
Conversion of a reporter gene for mitochondrial gene expression using
iterative mega-prime PCR. Gene. 230: 241 - 247 1999.

14
Engelsen, Bernt A; Aarli,  Johan A
Specialreference to mitochondrial encephalomyopathy and therapy
resistant epilepsy. Advances in Clin Neurosci. 9: 275 - 289 1999.

15
Gilhus, NE
Fordypningsstillinger, fordypningstid og klinisk forskning ved
Haukeland sykehus. Tidsskr Nor Legeforen. 119: 3771 - 3773 1999.

16
Gilhus, NE
Migrene - generelle prinsipper for ikke-medikamentell behandling.
Terapianbefaling; behandling av migrene. Nytt om legemidler. 22: 32 - 34
1999. ISSN 0807-1063

17
Gilhus, NE
Research improves neurorehabilitation. WFNR Update. 3: 3, 2 - 3 1999.

18
Hofman, S; Tiranti, V; Comi, G-P; Uziel, G; Meitinger, T; Zeviani, M;
Jacksch, M; Galimberti, C; Bezold, C; Lulli, L; Freisinger, P; Bindoff,
Laurence A
Loss of function SURF I mutations in cytochrome c oxidase deficiency. Ann
Neurol. 161 - 166 1999.

19
Jorga, KM; Larsen,  JP; Beiske,  A; Schleimer,  M; Fotteler,  B; Schmitt,  M;
Moe,  B
The effect of tolcapone on the pharmacokinetics of enserazide. Eur Neurol.
6: 211 - 219 1999.

20
Karlsen, Karen H; Larsen, Jan Petter; Tandberg, Elise
Fatigue in Parkinson's disease. Mov Disord. 237: 237 - 241 1999.

21
Karlsen, Karen H; Larsen,  Jan Petter; Tandberg,  Elise; Mæland,  JG
The influence of clinical and demographic variables on quality of     life
in patients with Parkinson's disease. J Neurol Neurosurg Psychiat. 66: 431
- 435 1999.

22
Korczyn, AD; Brunt,  ER; Larsen,  Jan Petter; Nagy,  Z; Poewe,  WH;
Ruggieri,  S
A 3-year randomized trial of ropinirole and bromocriptine in early
Parkinson's disease. Neurology. 53: 364 - 370 1999.

23
Larsen, Jan Petter; Boas,  J; Erdal,  JE
Long-term observation shows that selegiline delays the clinical
disease progression in patients with early Parkinson's disease. Eur Neurol.
6: 539 - 547 1999.

24
Myhr, Kjell-Morten; Raknes, G; Nyland, Harald; Vedeler, C
Immunoglobulin G Fc-receptor (Fc gamma R) IIA and IIIB polymorphisms
related to disability in MS. Neurology. 52: 1771 - 1776 1999.

25
Myhr, Kjell-Morten; Riise, Trond; Lilleås, F.E.G; Beiske, T.G; Celius, E.G.;
Edland, A.; Jensen, Dag; Larsen, J.P.; Nilsen, R.; Nortvedt, Monica Wammen;
Smievoll, Alf Inge; Vedeler, Christian et al.
Interferon-alpha 2a reduces MRI disease activity in
relapsing-remittingmultiple sclerosis. Neurology. 52: 5, 1049-1056
1999-03-23.

26
Myhr, Kjell-Morten; Nyland, Harald
Rapport fra internasjonalt MS-møte. MS-posten. 8: 8 - 11 1999.

27
Myhr, Kjell-Morten; Nyland, Harald
Rapport fra internasjonalt MS-møte i Basel. MS-bladet. 16 - 17 1999.

28
Nortvedt, Monica Wammen; Riise, Trond; Myhr, Kjell-Morten; Nyland, Harald I
Perfomance of the SF-12 Health Survey in a population of multiple
sclerosis patients. Quality of Life Research. Kluwer Academic Publishers 8:
7, 616 London 1999. The 6th Annual Conference of the International Society
for     Quality of Life Research. 3-6 november 1999.

29
Nortvedt, Monica Wammen; Riise, Trond; Myhr, Kjell-Morten; Nyland, Harald
Quality of life in multiple sclerosis: Measuring the disease effects more
broadly. Neurology. 53: 1091-1103 1999-09.

30
Nortvedt, Monica Wammen
The SF-36 summary scores underestimate mental health problems in
multiple sclerosis patients. Quality of Life Resaerch. Kluwer Academic
Publishers 7, 616 London 1999. The 6th Annual Conference of the
International Society for     Quality of Life Research. 3-6 november 1999.

31
Nortvedt, Monica Wammen; Riise, Trond; Myhr, Kjell-Morten; Nyland, Harald;
Hanestad, Berit Rokne
Type I interferons and the quality of life of multiple sclerosis patients.
Results from a clinical trial on interferon alfa-2a. Multiple Sclerosis. 5:
317-322 1999.

32
Nyland, H
Aktivitetsrapport fra Det Nasjonale Kompetansesenter for MS. MS-bladet. 4,
4 - 5 1999.

33
Pang, J; Allotey, R; Wadia, N; Sasaki, H; Bindoff, Laurence A; Chamberlain,
S
A common disease haploltype segretating in spinocerebellar ataxia 2
(SCA2) pedigrees of diverse ethnic origin. Eur J Hum Genet. 841 - 845 1999.

34
Romi, F; Kråkenes, J; Thomassen, L; Tysnes, Ole-Bjørn
Dolikoektasi av intrakraniale arterier og hjerneslag. Tidsskr Nor Lægeforen.
119: 3004 - 3005 1999.

35
Skeie, Geir Olve; Pandey,  JP; Aarli,  Johan A; Gilhus,  Nils Erik
TNFB polymorphisms in myasthenia gravis. Arch Neurol. 56: 457 - 461 1999.

36
Skouen, Jan Sture
Protein markers in cerebrospinal fluid in sciatica. A clinical        and
experimental study. - dr.med. 1 b. Universitet i Bergen 1999. ISBN
82-7788-073-1

37
Sominier, F; Skeie, GO; Aarli, Johan A; Trojaborg, W
EMG evidence of myopathy and the occurrence of titin autoantibodies   in
patients with myasthenia gravis. Eur J Neurol. 6: 555 - 563 1999.

38
Tandberg, E; Larsen, JP; Karlsen, K
Expressive daytime sleepiness and sleep benefit in Parkinson's
disease. A community-based study. Mov Disord. 14: 922 - 927 1999.

39
Thomassen, L; Waje-Andreassen,  U; Maintz,  C
Trombolytisk behandling ved akutt hjerneinfarkt - en tidsstudie ved
organisering av et nytt behandlingstilbud. Tidsskr Nor Lægeforen. 119: 2978
- 2981 1999.

40
Trapp, BD; Bø, Lars; Mørk, Sverre; Chang, A
Pathogenesis of tissue injury in MS lesions. Neuroimmunol. 98: 49 - 56 1999.

41
Tysnes, Berit Bølge; Mahesparan, Ruby; Thorsen, Frits Alan; Haugland, Hans
Kristian; Porwol, T; Enger, PØ; Lund-Johansen, M; Bjerkvig, Rolf
Laminin expression by glial fibrillary acidic protein positive cells  in
human gliomas. International Journal of Developmental Neuroscience. 17: 5/6,
531 - 539 1999. ISSN 0736-5748

42
Vedeler, C; Conti, G; Fujioka, T; Scarpini, E; Rostami, A
The expression of CD59 in experimental allergic neuritis. J Neurol Sci. 165:
154 - 159 1999.


<- forrigeinnholdneste ->